Oncotarget

Research Papers:

Predicting castration-resistant prostate cancer after combined androgen blockade

Miao He, Haina Liu, Jingyi Cao, Qian Wang, Haiting Xu and Yufeng Wang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:105458-105462. https://doi.org/10.18632/oncotarget.22246

Metrics: PDF 416 views  |   HTML 936 views  |   ?  


Abstract

Miao He1, Haina Liu1, Jingyi Cao2, Qian Wang2, Haiting Xu3 and Yufeng Wang1

1Department of Nuclear Medicine, Xuzhou Cancer Hospital, Jiangsu Province, Xuzhou, China

2Department of Urology, Xuzhou Cancer Hospital, Jiangsu Province, Xuzhou, China

3Department of Radiotherapy and Oncology, Xuzhou Cancer Hospital, Jiangsu Province, Xuzhou, China

Correspondence to:

Yufeng Wang, email: wangyufengxz@163.com

Keywords: prostate cancer; bone metastasis; bone scan; combined androgen blockade; castration resistance

Received: March 24, 2017    Accepted: October 02, 2017    Published: November 01, 2017

ABSTRACT

This study analyzed 99Tcm-MDP bone scans and investigated factors influencing early-stage castration resistance in prostate cancer (CRPC) patients with bone metastasis. We retrospectively analyzed clinical data from 92 patients with bone metastatic prostate cancer treated with maximal androgen blockade. Patients were imaged with 99Tcm-MDP bone scan to detect metastases, and prostate specific antigen (PSA) values were measured regularly. Before treatment, 464 total bone metastases were detected in the 92 patients, with pelvic bone metastases accounting for about 30.6% of the total. After combined androgen blockade treatment, median CRPC occurrence time was 23 months. A longer time to reach the lowest PSA value was an independent predictor of early-onset CRPC (occurrence <1 year after treatment). Our findings suggest that 99Tcm-MDP bone scans are useful for diagnosing prostate cancer bone metastasis and grading. Patients with Gleason scores>8, higher PSA values after treatment, and shorter times to reach the lowest PSA value had poorer responses to combined androgen blockade treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22246